HB Wealth Management LLC boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 7.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,848 shares of the medical research company's stock after buying an additional 762 shares during the period. HB Wealth Management LLC's holdings in Edwards Lifesciences were worth $1,032,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. ETF Managers Group LLC boosted its holdings in shares of Edwards Lifesciences by 5.0% during the 4th quarter. ETF Managers Group LLC now owns 8,167 shares of the medical research company's stock worth $1,067,000 after purchasing an additional 387 shares during the last quarter. IHT Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 53.6% during the 4th quarter. IHT Wealth Management LLC now owns 7,779 shares of the medical research company's stock worth $1,008,000 after purchasing an additional 2,715 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of Edwards Lifesciences by 8.3% during the 4th quarter. LPL Financial LLC now owns 285,359 shares of the medical research company's stock worth $36,968,000 after purchasing an additional 21,931 shares during the last quarter. State Street Corp boosted its holdings in shares of Edwards Lifesciences by 3.7% during the 4th quarter. State Street Corp now owns 26,920,713 shares of the medical research company's stock worth $3,487,578,000 after purchasing an additional 948,638 shares during the last quarter. Finally, Alpha Paradigm Partners LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $194,000. 81.33% of the stock is currently owned by hedge funds and other institutional investors.
Get Edwards Lifesciences alerts:Insider Activity at Edwards Lifesciences
In related news, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $84.17, for a total transaction of $1,672,878.75. Following the completion of the sale, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,244,402.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the business's stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $90.94, for a total transaction of $611,571.50. Following the sale, the vice president now owns 62,561 shares in the company, valued at $5,689,297.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 19,875 shares of the business's stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $84.17, for a total transaction of $1,672,878.75. Following the sale, the chief executive officer now owns 157,353 shares in the company, valued at approximately $13,244,402.01. The disclosure for this sale can be found here. Insiders sold a total of 86,128 shares of company stock valued at $8,223,839 over the last ninety days. Insiders own 1.29% of the company's stock.
Edwards Lifesciences Stock Up 0.7 %
EW stock opened at $84.74 on Friday. Edwards Lifesciences Co. has a 12 month low of $82.92 and a 12 month high of $131.73. The firm has a market cap of $52.53 billion, a PE ratio of 36.68, a P/E/G ratio of 2.49 and a beta of 1.14. The firm has a 50 day simple moving average of $97.09 and a 200 day simple moving average of $101.68. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60.Edwards Lifesciences (NYSE:EW – Get Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, meeting the consensus estimate of $0.63. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the business earned $0.64 earnings per share. The business's quarterly revenue was down .2% on a year-over-year basis. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on EW. Cowen lowered their target price on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Morgan Stanley decreased their price objective on Edwards Lifesciences from $136.00 to $119.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. Truist Financial decreased their price objective on Edwards Lifesciences from $117.00 to $112.00 and set a "buy" rating on the stock in a report on Thursday. Canaccord Genuity Group cut Edwards Lifesciences from a "buy" rating to a "hold" rating and decreased their price objective for the company from $115.00 to $106.00 in a report on Friday, July 29th. Finally, Stifel Nicolaus decreased their price objective on Edwards Lifesciences from $128.00 to $115.00 in a report on Monday, July 18th. Three equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $125.81.
Edwards Lifesciences Profile
(Get Rating)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Further Reading
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.